HomePeripheral Arterial Disease

Peripheral Arterial Disease

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

One year results from the TOBA II study were presented in the late-breaking scientific session by William Gray, M.D., System Chief, Division of Cardiovascular Disease at Main Line Health, President, Lankenau Heart Institute and Principal Investigator for the TOBA II trial.

Intact Vascular Reports Enrollment Completion of the Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial

The TOBA III study is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System® in combination with the Medtronic IN.PACT™ Admiral™ drug-coated balloon in the treatment of peripheral arterial disease in the superficial femoral and popliteal arteries.

TOBA BTK Trial One-Year Clinical Study Results Published in Catheterization and Cardiovascular Intervention

This multi-center pilot study focused on collecting data supporting the safety and performance of the Tack Endovascular System® in subjects with Critical Limb Ischemia (CLI) due to vascular disease below the knee.

FDA Approves 6-Month Primary Endpoint for the Tack Endovascular System in Below the Knee Disease

The TOBA II BTK study enrolled its first patient in February, 2017 and is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System in combination with standard balloon angioplasty in the popliteal and tibial arteries for the treatment of critical limb ischemia

Intact Vascular Announces Completion of Enrollment in the Tack Optimized Balloon Angioplasty II (TOBA II) Clinical Trial

The TOBA II trial is a prospective, multi-center, two-arm, non-randomized study designed to investigate the safety and efficacy of the Tack Endovascular System in combination with standard or drug coated balloon (DCB) angioplasty in the arteries above the knee.